According to a recent LinkedIn post from Briya, CEO David Lazerson has outlined his view of how artificial intelligence is evolving into core operational infrastructure for medical and biopharma R&D. The post, referencing comments in Citeline’s Scrip Asks feature on 2026 biopharma trends, emphasizes the need for large‑scale analysis of distributed clinical data without compromising patient privacy.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The company’s LinkedIn post highlights federated learning and privacy‑enhancing technologies as foundational for the next era of AI‑driven research. It further suggests that organizations investing early in these technologies may be better positioned to convert AI from a theoretical promise into practical performance gains, potentially accelerating drug discovery cycles and improving competitive positioning in data‑intensive segments of biopharma.